ADRA2A rs553668: Autonomic Reactivity and Metabolic Traits
The single-nucleotide polymorphism rs553668 is located in the ADRA2A gene, which codes for the alpha-2A adrenergic receptor. This receptor acts as an essential negative feedback regulator in the sympathetic nervous system, dampening the release of norepinephrine. Research suggests rs553668 may modulate autonomic reactivity, vascular tone under physical stress, and aspects of fasting glycemic regulation, though the overall clinical evidence remains preliminary.
What each genotype means
Typical autonomic and receptor regulation
You carry two copies of the C allele for rs553668 (also reported as the A allele in forward-strand notations such as c.*427A>G or DraI restriction polymorphism). Research shows that this common baseline genotype is generally linked with typical alpha-2A adrenergic receptor expression and baseline noradrenergic tone. While candidate studies suggest slight variations in stress reactivity and attention measures, findings remain preliminary and have not shown large standalone clinical effects.
Carried by approximately 55% to 60% of people of European ancestry and is the predominant genotype across most global populations.
Intermediate adrenergic receptor reactivity
You carry one copy of the T variant allele (reported as the G allele on the positive strand in some publications). Studies in neurocognitive performance and autonomic response have observed minor shifts in sustained attention and presynaptic norepinephrine regulation in heterozygous carriers, though effects are subtle. If reviewing response or dosing for medications that act on adrenergic or stimulant pathways, discuss your overall health profile with your clinician or pharmacist.
Found in roughly 35% to 40% of individuals of European descent and somewhat less frequently in East Asian populations.
Altered adrenergic receptor expression
You carry two copies of the T variant allele (corresponding to the homozygous GG genotype in some positive-strand literature). In experimental and candidate association studies, this genotype has been linked to increased alpha-2A adrenergic receptor expression, subtle alterations in autonomic stress responsiveness, and minor differences in attentional variability, though findings across diverse populations remain limited and mixed. Anyone evaluating medications affecting the noradrenergic system should consult a clinician or pharmacist regarding personalized care.
Present in approximately 5% to 8% of individuals of European ancestry and occurs at lower frequencies in several non-European populations.
Understanding rs553668 and the ADRA2A Locus
The single-nucleotide polymorphism rs553668 is mapped to human chromosome 10 within the ADRA2A gene. Historically examined in physiological literature via restriction fragment length polymorphism analysis (frequently designated as the DraI RFLP or 1780C>T), this variant represents a transition located in the non-coding 3' untranslated region (3' UTR) or flanking sequence. Because it does not alter the underlying amino acid sequence of the receptor protein, researchers hypothesize that rs553668 acts either as an expression quantitative trait locus (eQTL)—altering mRNA stability and transcription levels—or as a linked genomic proxy for other regulatory variations situated along the noradrenergic receptor locus.
The Biological Function of the Alpha-2A Adrenoceptor
The ADRA2A gene provides instructions for producing the alpha-2A adrenergic receptor, a cell-surface G-protein-coupled receptor (GPCR) predominantly coupled to the inhibitory G(i/o) signaling pathway. Upon binding catecholamines such as norepinephrine and epinephrine, the receptor suppresses cyclic adenosine monophosphate (cAMP) production. In presynaptic terminals across both the central and sympathetic nervous systems, alpha-2A receptors act as critical auto-inhibitory brakes, curbing further neurotransmitter release. Additionally, post-synaptic receptors located on vascular smooth muscle, pancreatic beta cells, and adipose tissue contribute to blood pressure maintenance, suppression of insulin secretion, and the moderation of lipolysis during acute physiologic or psychological stress.
Associated Traits and Scientific Evidence Strength
Scientific investigations have explored associations between rs553668 and several physiological traits, including autonomic reactivity, vascular conductance, and metabolic indices. Some physiological cohorts have observed that individuals carrying specific alleles demonstrate differences in exercise-induced muscle vasodilation and heart rate variability metrics. Other prospective metabolic studies have linked the variant to minor variations in baseline fasting glucose and downstream insulin secretion patterns over multi-year follow-ups. However, pharmacological databases such as PharmGKB and ClinPGx document that attempts to link rs553668 to differential drug responses—such as methylphenidate efficacy in ADHD or dexmedetomidine dosing—have consistently failed to reach statistical significance after correcting for multiple comparisons. Consequently, the collective evidence supporting rs553668 remains limited and largely exploratory.
Genomic Distribution and Population Frequency
Data from large-scale reference datasets, including the Genome Aggregation Database (gnomAD) and dbSNP, demonstrate that rs553668 is a common polymorphism worldwide, although its exact allele distribution exhibits moderate variability across distinct ancestral populations. In populations of European ancestry, the minor allele frequency is approximately 0.25, meaning that roughly one in four alleles is the minor variant. Heterozygous genotypes are widespread, while homozygous minor individuals represent a relatively small portion of global cohorts. Because physiological studies on this variant have primarily occurred within restricted demographic groups, findings observed in one ancestral background cannot be assumed to apply uniformly across different genetic ancestries.
Clinical Utility and Lifestyle Context
At present, rs553668 possesses no established clinical validity or diagnostic utility. It cannot determine individual cardiovascular risk, diagnose autonomic dysfunction, or predict therapeutic success for noradrenergic medications. Consumers should be cautious not to draw medical conclusions from direct-to-consumer genetic readouts of this variant. Any decisions regarding cardiovascular health, metabolic management, or prescription regimens must be made in consultation with a physician or pharmacist, guided by standard diagnostic tests, validated clinical biomarkers, and established practice guidelines.
How common is this variant?
The rs553668 variant is common across diverse populations, with a minor allele frequency of approximately 0.25 among European cohorts according to gnomAD.
Frequently asked questions
Does my rs553668 genotype mean I have autonomic dysfunction?
No, rs553668 is a common genetic variation and is not a clinical diagnostic marker. While small research cohorts study this locus to observe how the sympathetic nervous system reacts to stress, carrying any genotype at this position does not diagnose or predict autonomic disorders.
Can rs553668 predict how I will respond to ADHD medication?
No. Although researchers have examined whether ADRA2A variants influence response to stimulants like methylphenidate, published studies in pharmacogenomic repositories have shown no statistically significant association with rs553668. Any questions about ADHD medications should be discussed directly with a prescribing healthcare provider.
Why do some studies refer to DraI RFLP or alleles A and G instead of C and T?
Older genetic literature identified rs553668 using the restriction enzyme DraI, referring to it as the DraI polymorphism. Furthermore, because DNA consists of two complementary strands, dbSNP reports the variant as C/T on one strand, whereas assays reporting the opposite strand refer to G/A.
Does carrying the TT genotype cause type 2 diabetes?
No. While some metabolic observational studies have reported modest statistical associations between the homozygous alternate genotype and fasting glucose levels over time, rs553668 is not a causal gene mutation for diabetes. Metabolic health is driven primarily by overall lifestyle, diet, physical activity, and complex polygenic factors.
Sources & further reading
Educational information only, last refreshed 9/14/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs553668?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29